Developing a Respiratory Drug for: Asthma Chronic Obstructive Pulmonary Disease (COPD) Chronic Bronchitis Emphysema Cystic Fibrosis (CF) Interstitial Lung Disease (ILD) Regulation of Nitric Oxide (NO) Sodium Pyruvate Phase I/II Study of Mild Asthmatics Phase I/II Nitric Oxide (NO) Study Phase I/II Study in Severe COPD Patients Phase I/II Double Blinded Placebo Controlled Study in Severe COPD Patients Anti-Viral Effects of Nitric Oxide (NO) Pyruvate in Cancer Prevention & Treatment Sarcoidosis

N115 Patents 6,689,810 issued February 10, 2004 Title: Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide. 6,482,856 issued November 19, 2002 Title: Method and composition for treating mammalian disease caused by inflammatory response. Claim: A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator, which reduces the undesired inflammatory response and is an antioxidant. 5,952,384 issued September 14, 1999 Title: Method and composition for treating mammalian diseases caused by inflammatory response. Claim: A method for treating airway diseases in mammals caused by mammalian cells involved in the inflammatory response (with pyruvate). 5,939,459 issued August 17, 1999 Title: Method and composition for treating mammalian disease caused by inflammatory response. Claim: A method for treating emphysema in mammals caused by mammalian cells involved in the inflammatory response (with pyruvate). 5,798,388 issued August 25, 1998 Title: Method and composition for treating mammalian diseases caused by inflammatory response. Claim: A method for treating asthma in mammals caused by mammalian cells involved in the inflammatory response (with pyruvate).

The FDA has determined that N115 has sufficient safety toxicology and clinical data to proceed with the multi-dose, extended use, clinical trials. Phase II studies will focus on asthmatics and COPD patients. On the basis of existing clinical data, EmphyCorp is confident that its Investigative New Drug, N115, can and will be used for maintenance or continuous treatment of patients over extended periods of time. The Company believes that N115 will set the standard in the pharmaceutical industry for the treatment of major pulmonary diseases.